Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Howard S. Hochster; Michael D. Green; Ronald H. Blum; James C. Wernz; James L. Speyer; Franco M. Muggia

doi:10.1007/BF00179596

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Howard S. Hochster, Michael D. Green^*, Ronald H. Blum, James C. Wernz, James L. Speyer, Franco M. Muggia

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

Original language	English
Pages (from-to)	275-278
Number of pages	4
Journal	Investigational New Drugs
Volume	4
Issue number	3
DOIs	https://doi.org/10.1007/BF00179596
State	Published - Sep 1986
Externally published	Yes

Keywords

4-demethoxydaunorubicin
idarubicin
non-small cell lung cancer
oral cytotoxic
phase II clinical trial

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00179596

Cite this

@article{9ce79f0ec9d44d39a4de397241c3e0d1,

title = "Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial",

abstract = "Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.",

keywords = "4-demethoxydaunorubicin, idarubicin, non-small cell lung cancer, oral cytotoxic, phase II clinical trial",

author = "Hochster, {Howard S.} and Green, {Michael D.} and Blum, {Ronald H.} and Wernz, {James C.} and Speyer, {James L.} and Muggia, {Franco M.}",

year = "1986",

month = sep,

doi = "10.1007/BF00179596",

language = "אנגלית",

volume = "4",

pages = "275--278",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

AU - Hochster, Howard S.

AU - Green, Michael D.

AU - Blum, Ronald H.

AU - Wernz, James C.

AU - Speyer, James L.

AU - Muggia, Franco M.

PY - 1986/9

Y1 - 1986/9

N2 - Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

AB - Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

KW - 4-demethoxydaunorubicin

KW - idarubicin

KW - non-small cell lung cancer

KW - oral cytotoxic

KW - phase II clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0023026033&partnerID=8YFLogxK

U2 - 10.1007/BF00179596

DO - 10.1007/BF00179596

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 3469171

AN - SCOPUS:0023026033

SN - 0167-6997

VL - 4

SP - 275

EP - 278

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this